Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug‐eluting stents-Reference-Cited by-同舟云学术

Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug‐eluting stents

Published:2021-06-24 Issue: Volume: Page:
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Catheter Cardiovasc Interv

Author:

Koh Jin‐Sin¹²^ORCID,Gogas Bill D.¹³,Kumar Sandeep⁴,Benham James J.⁵,Sur Sanjoli⁴,Spilias Nikolaos¹,Kumar Arnav¹,Giddens Don P.⁴,Rapoza Richard⁵,Kereiakes Dean J.⁶,Stone Gregg⁷,Jo Hanjoong⁴,Samady Habib¹⁸

Affiliation:

1. The Andreas Gruentzig Cardiovascular Center, Division of Cardiology, Department of Medicine Emory University School of Medicine Atlanta GA USA

2. Division of Cardiology, Department of Internal Medicine, Gyeongsang National University School of Medicine Gyeongsang National University Hospital Jinju Republic of Korea

3. Nanjing First Hospital Nanjing Medical University Nanjing China

4. The Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University Atlanta Georgia USA

5. Abbott Vascular Santa Clara California USA

6. The Ohio Heart and Vascular Center, The Christ Hospital Cincinnati Ohio USA

7. NewYork‐Presbyterian Hospital Columbia University Medical Center, and the Cardiovascular Research Foundation New York New York USA

8. Northeast Georgia Health System Gainesville GA USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.29819

Reference35 articles.

1. Novel drug‐eluting stents for coronary revascularization;Gogas BD;Trends Cardiovasc Med,2014

2. Long‐term safety of bioresorbable scaffolds: insights from a network meta‐analysis including 91 trials;Kang SH;EuroIntervention,2018

3. Effect of technique on outcomes following bioresorbable vascular scaffold implantation: analysis from the ABSORB trials;Stone GW;J Am Coll Cardiol,2017

4. 3‐year clinical outcomes with everolimus‐eluting bioresorbable coronary scaffolds: the ABSORB III trial;Kereiakes DJ;J Am Coll Cardiol,2017

5. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30‐day and 1‐year results from the ABSORB IV randomised trial;Stone GW;Lancet,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scaffolds for drug delivery and tissue engineering: The role of genetics;Journal of Controlled Release;2023-07

2. Long-Term Intracoronary Structural and Vasomotor Assessment of the ABSORB Bioresorbable Vascular Scaffold;The American Journal of Cardiology;2022-04